# OnCo record dellphi-304 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/dellphi-304/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "dellphi-304", "NCT05740566" ;
  schema:name "DeLLphi-304"@en ;
  schema:alternateName "dellphi-304"@en ;
  schema:description "DeLLphi-304 was the first trial in which a T-cell engager improved survival in a common solid tumour."@en ;
  schema:url <https://onco.cc/trials/dellphi-304/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05740566> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2023-05-31" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/dll3/> ;
  onco:drugs <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/amrubicin/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:people <https://onco.cc/people/luis-paz-ares/>, <https://onco.cc/people/charles-rudin/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/> .